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Background: Treatment approaches in malignant pleural mesothe-
lioma (MPM) patients range from mere palliation to aggressive
anticancer therapy, and there is currently no consensus on the
optimal therapeutic strategy. In 1999, we began a phase II study to
investigate four-modality treatment of advanced stage MPM.
Methods: From 1999 to 2004, 49 patients with International Me-
sothelioma Interest Group stage II–III MPM underwent four-modal-
ity treatment with intrapleural preoperative interleukin-2 (18  106
UI/day for 3 days), pleurectomy/decortication, intrapleural postop-
erative epidoxorubicin (25 mg/m2 for 3 days), interleukin-2 (18 
106 UI/day for 3 days), adjuvant radiotherapy (30 Gy), systemic
chemotherapy (cisplatin 80 mg/m2 day 1, gemcitabine 1250 mg/m2
days 1 and 8 for up to six courses) and long-term subcutaneous
interleukin-2 (3  106 UI/day on 3 days per week).
Results: Patients included 41 men and eight women with a median
age of 61 years (range, 41–77). All patients were diagnosed with
MPM by thoracoscopy before inclusion. There was no postoperative
mortality. Postoperative morbidity included bleeding (n  1) and
arrhythmias (n  3). After a median follow-up of 59 months (range,
14–81), 13 patients are still alive and the median actuarial survival
is 26 months (31 and 21 months for stages II and III, respectively).
The 2- and 5-year actuarial survival rates were 60.2% and 23.3%,
respectively. Baseline Eastern Cooperative Oncology Group perfor-
mance status significantly influenced survival time (p  0.02).
Conclusion: The four-modality treatment that we adopted for ad-
vanced-stage MPM was feasible, well tolerated by most of the
patients, and produced a favorable median survival. This treatment
approach warrants further investigation.
Key Words: Mesothelioma, Multimodality treatments, Pleurec-
tomy, Chemotherapy, Immunotherapy.
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Malignant pleural mesothelioma (MPM) is an aggressive,uniformly fatal tumor. The median survival time from
diagnosis in MPM patients receiving palliative care is 7
months.1 More than 80% of MPM cases are directly related to
asbestos exposure up to 40 years earlier.2 Because of the
latency between exposure to the causative agent and tumor
development, the incidence of MPM is currently increasing
worldwide; 250,000 deaths due to MPM are predicted to
occur in Western Europe in the next 30 years.3
MPM is difficult to treat because of its aggressive
nature. Patients are usually older at the time of diagnosis,
with comorbid conditions and invasive disease that may be
complicated by pleural effusion. Consequently, treatment
approaches in MPM patients range from mere palliation to
aggressive anticancer therapy.3
Surgical therapy generally involves extrapleural pneu-
monectomy (EPP), an aggressive procedure involving resec-
tion of the visceral and parietal pleura, lung, pericardium, and
ipsilateral diaphragm, or pleurectomy/decortication (P/D), in
which the visceral, parietal, and pericardial pleura are re-
moved but the lung is spared. Neither EPP nor P/D has
long-term survival benefits,3,4 and, therefore, these proce-
dures are frequently conducted in conjunction with adjuvant
chemo- and radiotherapy.
Combination platinum- and/or anthracycline-based
chemotherapy appears to be superior to single-agent chemo-
therapy for MPM treatment.4 Nonetheless, combination che-
motherapy is generally associated with low (20%) response
rates and poor median survival times (6–12 months).4 The
most encouraging response rates have been observed with
premetrexed plus cisplatin (41%),5 and gemcitabine plus
cisplatin (48%).6 However, the question remains as to
whether chemotherapy should be administered in a pre- or
postoperative setting.
Radiotherapy has produced disappointing results in
MPM patients, but it does seem effective for symptom pal-
liation4 and the prevention of seeding along surgical scars.7
Immunotherapy agents, such as interleukin 2 (IL-2) or
interferon (IFN)- or IFN-, are suitable for administration
in combination with other anticancer treatments. IL-2 is a
lymphokine that enhances the cytotoxic response of activated
T cells and whose low serum level is correlated with poor
survival in patients with advanced cancer.8 It is effective,
with or without chemotherapy, in patients with melanoma,
metastatic renal cancer, and other solid tumors and, when
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administered via the intracavitary route, is superior to IFN-
or IFN- in neoplastic pleural effusions in patients with
mesothelioma, producing an overall response (OR) rate of
40%.8 In phase II studies, sequential therapy with intrapleu-
ral9 or intravenous10 IL-2 followed by subcutaneous IL-2
produced median survival times of 8.6 to 18.7 months in
MPM patients.9,10
There is currently no consensus in the literature on the
optimal treatment for MPM, and most centers adopt a mul-
timodal therapeutic strategy. Trimodality therapy has been
investigated in clinical studies; MPM patients undergoing
trimodal therapy with cytoreductive surgery and adjuvant
chemotherapy and radiotherapy achieved median survival
times of 13 to 19 months.11–14 Sugarbaker et al.12 demon-
strated that EPP and adjuvant chemotherapy was most effec-
tive among patients with positive prognostic parameters,
including epithelial histology, no nodal involvement, and
clear resection margins, who achieved high 2- and 5-year
survival rates (68% and 46%, respectively) and a median
survival time of 51 months.12 Thus, EPP is frequently con-
ducted in patients with positive prognostic factors, whereas
P/D may be more suitable for older patients or those with
more advanced disease and poorer performance at diagnosis.
In 1999, we began a phase II study to explore the
therapeutic efficacy of multimodal therapy comprising immu-
notherapy, surgery, chemotherapy, radiotherapy, and long-
term immunotherapy in patients with advanced (stage II–III)
MPM.
MATERIALS AND METHODS
Study Design
This study was designed as a phase II trial to evaluate
the feasibility of multimodal treatment with preoperative
intrapleural IL-2, surgery (P/D), postoperative intrapleural
epidoxorubicin and IL-2, radiotherapy, systemic chemother-
apy with cisplatin and gemcitabine, and long-term subcuta-
neous IL-2 therapy. Additionally, we aimed to determine the
patterns of local and distant disease recurrence after treat-
ment, and the rate of overall survival. The study design was
approved by the local ethics committee and all patients gave
written informed consent.
Patient Selection
Eligible patients were younger than 75 years of age
with histologically proven stage II or III MPM diagnosed by
thoracoscopy. Additional eligibility criteria included Eastern
Cooperative Oncology Group (ECOG) performance status of
2, no history of malignancy or chemo- or radiotherapy,
adequate bone marrow reserve (leukocytes 3500/L, plate-
lets 100,000/L), and adequate liver (bilirubin 1.5 mg/dL)
and renal function (serum creatinine1.5 mg/dL and creatinine
clearance 65 mL/min).
Treatment
The planned multimodal treatment schedule is de-
scribed in Table 1. During preoperative IL-2 treatment, acet-
aminophen was administered in patients with fever (38°C).
After 1 day of recovery, all the patients underwent a thora-
cotomy. At the operation, if the disease was minimal and
considered a stage I, the patient was excluded from the study
and underwent an extrapleural pneumonectomy. In case of
stage II or III MPM, we performed a P/D consisting of the
removal of the parietal and mediastinal pleura of the involved
areas of the visceral pleura, with minimal resection of the
lung if necessary. In case of minimal involvement of the
pericardium and diaphragm, they were resected and sutured;
however, they were never replaced with a mesh as for the
radical P/D (neither in case of a T3 tumor). At the end of the
surgical procedure, a lymph node sample was taken, and a
thin catheter (pigtail 12 French) was positioned for intrapleu-
ral drug administration. The catheter was removed 1 week
after the last instillation of postoperative IL-2.
During long-term postoperative IL-2 therapy, the pa-
tient’s immunologic profile was monitored via routine serum
samples, and IL-2 treatment was discontinued when there
was evidence of disease relapse.
Patient Assessment
At baseline, patients gave a complete medical history
and underwent a physical examination, a chest and upper
abdomen computed tomography (CT) scan, pulmonary func-
tion testing, echocardiography. Laboratory testing was con-
ducted. Tests to exclude distant metastases were performed
when clinically indicated. Patients were staged according to
the International Mesothelioma Interest Group (IMIG) stag-
ing system.15
Chemotherapy and IL-2 treatment toxicity was evalu-
ated according to the World Health Organization grading
system.
Patients were observed until death or the final date of
analysis for this report (December 2005). Survival was cal-
culated from the date of diagnosis until the date of death or of
the last follow-up. Physical examination and a CT scan of the
TABLE 1. Planned Sequential Multimodal Treatment
Schedule
Treatment Start Time
IP IL-2 18  106 UI/day for 3 days Preoperative
P/Da
IP epidoxorubicin 25 mg/m2 for 3 days 5–7 days after surgery
IP IL-2 18  106 UI/day for 3 days Immediately after
epidoxorubicin treatment
Radiation therapyb 30–45 days after surgery
Cisplatin 80 mg/m2 on day 1 and
gemcitabine 1250 mg/m2 on days 1
and 8 for 3–6 courses
1 mo after radiotherapy
SC IL-2 3  106 UI/day on 3 days per
week
1 mo after chemotherapy
IL-2, interleukin-2; P/D, pleurectomy/decortication; SC, subcutaneous.
a After 1 day of recovery, all patients underwent a thoracotomy to confirm the
disease severity according to IMIG staging criteria. Patients with stage I disease were
excluded from the study and underwent extrapleural pneumonectomy. Patients with
stage II or III MPM underwent P/D, which consisted of removal of the parietal and
mediastinal pleura or areas of the visceral pleura if they were involved, with minimal
resection of the lung if necessary. If involved, the pericardium or diaphragm was
resected and sutured.
b Radiation therapy aimed to treat all surgical scars while sparing the underlying
lung parenchyma.
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chest and upper abdomen were performed 1 month after the
end of radiation therapy and every 3 months thereafter. Local
tumor progression was defined according to radiographic
criteria; cytologic or histologic evidence of disease progres-
sion was not routinely obtained. Disease progression, accord-
ing to the Response Evaluation Criteria in Solid Tumors
Group (RECIST), was defined as at least 20% increase in the
sum of the longest diameters of target lesions.
Statistical Analysis
Survival was estimated using the Kaplan-Meier prod-
uct-limit method and survival curves were compared using
the log-rank test. The 2 test was used for comparison
between proportions, and Fisher’s exact test was used when
cell frequencies were small. Statistical analysis was con-
ducted using Stat-Soft software, and results are expressed as
mean  SD. A p value 0.05 was considered significant.
RESULTS
Patient Characteristics
From 1999 to 2004, 49 patients with IMIG stage II–III
MPM were enrolled in the study. Baseline demographics and
characteristics are listed in Table 2. All patients had the
diagnosis of MPM confirmed by thoracoscopy before inclu-
sion. Most patients had IMIG stage III disease, and an ECOG
performance status score of 1. Nine of the 40 patients
diagnosed with stage III tumors had N2 disease, whereas the
remaining patients had T3 tumors (Table 2).
Treatment Administration and Toxicity
We did not experience any postoperative mortality.
Postoperative complications included bleeding (n  1), ar-
rhythmias (n  3), and air leakage (n  6).
Intrapleural IL-2 and epidoxorubicin were administered
to all patients without dose reduction or interruption. All
patients experienced fever during treatment and required
antipyretic medication, and three patients had cutaneous com-
plaints (mostly desquamation), which spontaneously resolved
after treatment.
All patients received adjuvant systemic chemotherapy
with cisplatin and gemcitabine. Each patient received an
average of 5.3 cycles (range, two to six), and 259 cycles were
delivered in total. Median granulocyte, platelet, and hemo-
globin nadirs were 712 cells/mm3, 181,000 cells/mm3, and
10.5 g/dl, respectively; neutropenic fever occurred in 52
courses (20.1%). The most common nonhematologic toxici-
ties were mild or moderate alopecia, nausea/vomiting, and
gastrointestinal toxicity (Table 3).
Adjuvant radiotherapy, whose targets were the surgical
scars and eventual residual disease, was administered in all
patients. Four patients, referred by centers where the radio-
therapists refused the treatment patients, were excluded from
the analysis. Radiation therapy–related complications were
mild. Actinic pneumonia, which occurred in most patients,
was managed with corticosteroids.
Long-term subcutaneous IL-2 therapy was adminis-
tered for a median of 10 months (range, 1–36) and was well
tolerated. The only complications were eosinophilia, ob-
served in 37% of patients, and a mild fever, which was
managed with paracetamol 500 mg.
Survival and Disease Recurrence
After a median follow-up time of 59 months (range,
14–81) 13 patients are still alive. Five patients are radio-
graphically disease free, 37 had a local relapse, and seven had
both a local and systemic relapse.
The median survival time was 26 months; median
survival times for patients with stage II or III disease at
baseline were 31 and 21 months, respectively. The 2- and
5-year actuarial survival rates were 60.2% and 23.3%, respec-
tively (Figure 1). Baseline ECOG performance status was the
only factor to significantly influence survival time (p  0.02;
Figure 2).
DISCUSSION
The optimal treatment for MPM remains elusive. With
only limited data available from well designed, randomized
trials, it is not clear whether current single or combination
TABLE 3. Nonhematologic Toxicity of Adjuvant
Chemotherapy with Cisplatin and Gemcitabine by Number of
Cycles
Toxicity
World Health Organization Grade
0 1 2 3 4
Gastrointestinal 197 33 28 1 0
Alopecia 41 13 157 48 0
Infection 221 35 3 0 0
Cardiac 257 2 0 0 0
Nausea/vomiting 101 105 41 12 0
TABLE 2. Patient and Tumor Characteristics
Variable
No. of Patients
(n  49) %
Gender
Male 41 84.7
Female 8 16.3
Age, y
Median (range) 61 (range 41–77)
IMIG stage
II 9 18.4
III 40 81.6
Histologic subtype
Epithelial 39 79.6
Mixed 6 12.2
Sarcomatous 4 8.2
ECOG performance status
0 7 14.3
1 30 61.2
2 12 24.5
ECOG, Eastern Cooperative Oncology Group; IMIG, International Mesothelioma
Interest Group.
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treatments offer patients a clinically meaningful benefit on
survival and quality of life.
In this study, we sought to design a multimodal treat-
ment strategy that was sufficiently effective for treatment of
this aggressive disease, but did not unduly affect the quality
of life of patients. As a matter of fact, the selected treatment
strategy was of acceptable tolerability.
Results from our study indicate that our multimodal
treatment strategy produces a survival benefit in MPM pa-
tients; the median survival of 26 months with our treatment is
encouraging compared with the expected survival time of 9
months in MPM patients receiving palliative care.
The schedule of IL-2 administration in our treatment
protocol, which was based on the results of previous phase II
studies,9,10 is original. We aimed to induce maximal immu-
nologic improvement by administering intrapleural preoper-
atively and then adjuvant IL-2, in combination with epidoxo-
rubicin for treatment of local disease, followed by long-term
FIGURE 1. Kaplan-Meier curve of
overall survival time for all patients
(n  49).
FIGURE 2. Survival according to
Eastern Cooperative Oncology
Group (ECOG) performance status
at the time of diagnosis.
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subcutaneous IL-2. Endogenous IL-2 is depleted in all ad-
vanced tumors, particularly MPM, and the resulting decrease
in serum lymphocytes is an important prognostic factor for
survival.8
With regard to the surgical arm, our protocol dictated
that EPP was conducted in patients with IMIG stage I disease
who had acceptable lung and cardiac function, and P/D was
performed in patients with stage II or III disease. P/D is a less
radical procedure and is associated with fewer complications
than EPP; the morbidity rate for P/D is 25%, whereas signif-
icant complications occur in 50% of patients undergoing
EPP.3 Thus, patients undergoing P/D are able to tolerate
complex adjuvant multimodal therapy, as supported by evi-
dence from our study in which most patients completed all
scheduled treatment.
The selection of adjuvant intrapleural chemotherapy
with epidoxorubicin and systemic chemotherapy with cispla-
tin and gemcitabine was based on the high objective
response rates achieved with these drugs in clinical studies
in MPM patients.6,16,17 In our study, chemotherapy with
these agents was well tolerated and suitable for coadmin-
istration with IL-2.
Despite encouraging results with adjuvant radiation
therapy from one phase II study, in which MPM patients
receiving hemithoracic radiotherapy in conjunction with P/D
or EPP achieved a median survival time of 10 to 34 months
depending on the stage of the tumor,18 a recent retrospective
analysis suggests this strategy is not effective in MPM pa-
tients.19 This analysis found a median overall survival time of
13.5 months in MPM patients treated with P/D and adjuvant
radiotherapy, compared with 17 to 19 months in patients who
underwent EPP.19 However, it is notable that this analysis
found a median survival time of 13.9 months among stage III
and IV patients.19 It is obvious that lung toxicity during
radiation therapy is a minor concern after EPP. However, we
believe that radiation therapy, in combination with chemo-
and immunotherapy, may be useful in patients unable to
tolerate EPP who undergo P/D. Rusch et al.18 achieved an
amazing 10% incidence of local relapse, much better than our
89.7%, but we must wonder which is the most important
endpoint among local recurrence rate: overall survival or
quality of life. Whenever a low local relapse rate does not
match a long survival, it is not a crucial issue.
The four treatment modalities administered in our study
were chosen to produce optimal survival and local and
systemic control of MPM, without compromising the pa-
tient’s quality of life with overly aggressive therapy. Treat-
ments were selected based on data from clinical trials dem-
onstrating a treatment benefit with multimodal therapy,11–14
such as that by Sugarbaker et al.,12 who demonstrated, even
if excluding the perioperative deaths from the survival anal-
ysis, a median survival time of 19 months in patients receiv-
ing trimodal therapy with EPP and chemo- and radiotherapy.
Recently, in a phase I and II study, intraoperative intracavi-
tary hyperthermic chemotherapy was administered to en-
hance locoregional control of MPM. In 20 MPM patients
treated with P/D and intraoperative, intracavitary hyperther-
mic cisplatin lavage, the authors reported a median survival
time of 26 months.20 Furthermore, the use of P/D in our study
is supported by recent data from an animal study by Broom-
field et al.,21 which suggests that partial surgical debulking
followed by combination chemo- and immunotherapy in-
duces a long-term immunologic memory response.
Aggressive multimodal treatment with neoadjuvant
chemotherapy, similar to that used in advanced NSCLC, has
been investigated in MPM patients. In a pilot study by Weder
et al.,22 MPM patients receiving neoadjuvant cisplatin 80
mg/m2 and gemcitabine 1000 mg/m2 followed by EPP
achieved a response rate of 32% and, among 16 of the 19
patients who underwent EPP, the median survival time with
neoadjuvant chemotherapy was 23 months.22 Preliminary
data from an extension of this study, in which 29 of 61
patients completed treatment, indicate an excellent median
survival time of 26.3 months.23 However, the postoperative
complication rate was high (62%) and raises safety concerns,
supporting our rationale that a less aggressive treatment may
be appropriate for MPM patients. Final results from this study
are awaited with interest.
A drawback of our study design was the inability to
measure the quality of life. Although we observed positive
effects on this outcome, the study questionnaire did not allow
these results to be recorded.
In conclusion, our study supports the addition of local
and systemic immunotherapy to surgery, radio- and chemo-
therapy in MPM patients. In light of the poor life expectancy
of patients with MPM, we believe that it is important to avoid
aggressive treatment modalities, and to provide instead a
regimen that is tolerable and able to be completed by the
majority of patients. The observed 26-month median survival
with our multimodal treatment is extremely encouraging. Thus,
our four-modality regimen warrants further investigation in
clinical trials in MPM patients.
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